Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Xilio Therapeutics, Inc.

Get SEC filing alerts via email and in your feed for Xilio Therapeutics, Inc.

XLO

Xilio Therapeutics, Inc.

About Xilio Therapeutics, Inc.

Xilio Therapeutics is a biotech company developing tumor-activated immuno-oncology therapies that localize immune responses within the tumor microenvironment to enhance efficacy and reduce systemic toxicity. Its pipeline includes antibody, cytokine, and T cell engager candidates, leveraging proprietary masking platforms. The company focuses on innovative, highly selective treatments for solid tumors, with collaborations and a strong intellectual property portfolio supporting its mission to improve cancer outcomes.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Xilio Therapeutics, Inc.

1
1
Xilio Therapeutics, Inc. Xilio Therapeutics Reports $12.6M Revenue Growth and $9.5M Net Loss for Q1 2026

Via official filing (AI summary) | 23 days ago | 0 comments

2
1
Xilio Therapeutics, Inc. Xilio Therapeutics Reports 2025 Financial Results and Operational Progress

Via official filing (AI summary) | 2 months ago | 0 comments

3
1
Xilio Therapeutics, Inc. Xilio Therapeutics Reports $19.1 Million Revenue for Q3 2025, Net Loss Increases to $16.3 Million

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Xilio Therapeutics, Inc. Xilio Therapeutics Reports $8.1 Million Revenue for Q2 2025, Despite Operating Losses

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Xilio Therapeutics, Inc. Xilio Therapeutics Reports $2.93 Million Revenue and $13.27 Million Net Loss in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Xilio Therapeutics, Inc. Xilio Therapeutics Reports $58.2 Million Net Loss for 2024, Improved from Previous Year

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Xilio Therapeutics, Inc. Xilio Therapeutics Reports Improved Financial Results, Raises Doubts About Future Funding

Via official filing (AI summary) | over 1 year ago | 0 comments